Department of Radiology, School of Clinical Medicine, University of Cambridge, Box 218, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Eur Radiol. 2019 Oct;29(10):5559-5566. doi: 10.1007/s00330-019-6011-8. Epub 2019 Mar 19.
This prospective study evaluated the use of vascular, extracellular and restricted diffusion for cytometry in tumours (VERDICT) MRI to investigate the tissue microstructure in glioma. VERDICT-derived parameters were correlated with both histological features and tumour subtype and were also used to explore the peritumoural region.
Fourteen consecutive treatment-naïve patients (43.5 years ± 15.1 years, six males, eight females) with suspected glioma underwent diffusion-weighted imaging including VERDICT modelling. Tumour cell radius and intracellular and combined extracellular/vascular volumes were estimated using a framework based on linearisation and convex optimisation. An experienced neuroradiologist outlined the peritumoural oedema, enhancing tumour and necrosis on T2-weighted imaging and contrast-enhanced T1-weighted imaging. The same regions of interest were applied to the co-registered VERDICT maps to calculate the microstructure parameters. Pathology sections were analysed with semi-automated software to measure cellularity and cell size.
VERDICT parameters were successfully calculated in all patients. The imaging-derived results showed a larger intracellular volume fraction in high-grade glioma compared to low-grade glioma (0.13 ± 0.07 vs. 0.08 ± 0.02, respectively; p = 0.05) and a trend towards a smaller extracellular/vascular volume fraction (0.88 ± 0.07 vs. 0.92 ± 0.04, respectively; p = 0.10). The conventional apparent diffusion coefficient was higher in low-grade gliomas compared to high-grade gliomas, but this difference was not statistically significant (1.22 ± 0.13 × 10 mm/s vs. 0.98 ± 0.38 × 10 mm/s, respectively; p = 0.18).
This feasibility study demonstrated that VERDICT MRI can be used to explore the tissue microstructure of glioma using an abbreviated protocol. The VERDICT parameters of tissue structure correlated with those derived on histology. The method shows promise as a potential test for diagnostic stratification and treatment response monitoring in the future.
• VERDICT MRI is an advanced diffusion technique which has been correlated with histopathological findings obtained at surgery from patients with glioma in this study. • The intracellular volume fraction measured with VERDICT was larger in high-grade tumours compared to that in low-grade tumours. • The results were complementary to measurements from conventional diffusion-weighted imaging, and the technique could be performed in a clinically feasible timescale.
本前瞻性研究采用血管、细胞外和限制扩散的肿瘤细胞分析(VERDICT)MRI 来研究脑胶质瘤的组织微观结构。VERDICT 衍生参数与组织学特征和肿瘤亚型相关,还用于探索肿瘤周围区域。
14 例连续未经治疗的疑似脑胶质瘤患者(43.5±15.1 岁,男性 6 例,女性 8 例)接受了包括 VERDICT 建模的扩散加权成像。使用基于线性化和凸优化的框架估计肿瘤细胞半径以及细胞内和细胞内外/血管容积。一位经验丰富的神经放射学家在 T2 加权成像和对比增强 T1 加权成像上勾画肿瘤周围水肿、增强肿瘤和坏死区。将相同的感兴趣区域应用于配准的 VERDICT 图谱,以计算微观结构参数。使用半自动软件分析病理切片以测量细胞密度和细胞大小。
所有患者均成功计算了 VERDICT 参数。影像学结果显示高级别胶质瘤的细胞内容积分数高于低级别胶质瘤(分别为 0.13±0.07 与 0.08±0.02,p=0.05),细胞外/血管容积分数有较小的趋势(分别为 0.88±0.07 与 0.92±0.04,p=0.10)。低级别胶质瘤的常规表观扩散系数高于高级别胶质瘤,但差异无统计学意义(分别为 1.22±0.13×10mm/s 与 0.98±0.38×10mm/s,p=0.18)。
这项可行性研究表明,VERDICT MRI 可用于使用简化方案探索脑胶质瘤的组织微观结构。组织结构的 VERDICT 参数与组织病理学发现相关。该方法有望成为未来诊断分层和治疗反应监测的潜在测试方法。
• VERDICT MRI 是一种先进的扩散技术,在这项研究中,它与手术获得的脑胶质瘤患者的组织病理学发现相关。
• 与低级别肿瘤相比,高级别肿瘤的 VERDICT 测量的细胞内容积分数更大。
• 结果与常规扩散加权成像的测量结果互补,并且该技术可以在临床可行的时间范围内进行。